Preclinical analysis of treosulfan in combination with total body irradiation as conditioning regimen prior to bone marrow transplantation in rats

References

• Davis, W., Ross, W. C. The formation of epoxides from cytotoxic polyol methanesulphonates under physiological conditions. Biochem Pharmacol. 1963,12,915–7.
   PubMedGoogle Scholar
• Feith, P.W. Studies on Epoxide formation from (2S,3S)-Threitol 1,4-Bismethanesulfonate. The preparation and biological activity of (2S, 3S) - 1,2-epoxy-3,4-butanediol 4-methanesulfonate. J Med Chem. 1970,13(6), 1173–5.
   PubMedGoogle Scholar
• Hilger, R.A., Harstrick, A., Eberhardt W., Oberhoff C., Skorzec M., Baumgart J., et al. Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. Cancer Chemother Pharmacol. 1998,42(2),99–104.
   PubMedGoogle Scholar
• Hartley, J. DNA alkylation and interstrand cross-linking by treosulfan. Br J Cancer. 1999,79(2),264–6.
   PubMedGoogle Scholar
• Fennelly, J. Treosulfan (dihydroxybusulphan) in the management of ovarian carcinoma. Br JObstet Gynaecol. 1977,84(4),300–3.
   PubMedGoogle Scholar
• Duncan, I.D., Clayton, L.A. Combination chemotherapy of ovarian carcinoma with cisplatinum and treosulfan–a phase II study. Br J Obstet Gynaecol. 1985,92(7),762–7.
   PubMedGoogle Scholar
• Masding, J., Sarkar, T.K., White, W.F., Barley, V.L., Chawla, S.L., Boesen, E. et al. Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma. Br J Obstet Gynaecol. 1990,97(4),342–51.
   PubMedGoogle Scholar
• Gropp, M, Meier, W., Hepp, H. Treosulfan as an effective second-line therapy in ovarian cancer. Gynecol Oncol. 1998,71(1),94–8.
   PubMedGoogle Scholar
• Breitbach, G.P., Meden, H., Schmid, H., Kuhn, W., Sass, G., Schach, S. et al. Treosulfan in the treatment of advanced ovarian cancer: A randomised co-operative multicentre phase III-study. Anticancer Res. 2002,22(5),2923–32.
   PubMedGoogle Scholar
• Köpf-Maier, P., Sass, G. Antitumor activity of treosulfan against human breast carcinomas. Cancer Chemother Pharmacol. 1992,31(2),103–10.
   PubMedGoogle Scholar
• Köpf-Maier, P., Sass, G. Antitumor activity of treosulfan in human lung carcinomas. Cancer Chemother Pharmacol. 1996,37(3),211–21.
   PubMedGoogle Scholar
• Köpf-Maier, P. The alkylator treosulfan shows activity towards human renal-cell carcinoma in vivo and in vitro. In Vivo (Athens, Greece). 1998,12(3),275–88.
   Google Scholar
• Neale, M.H., Myatt, N., Cree, I.A., Kurbacher, C.M., Foss, A.J., Hungerford, J.L. et al. Combination chemotherapy for choroidal melanoma: Ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer. 1999,79(9–10),1487–93.
   PubMedGoogle Scholar
• Neuber, K., tom Dieck, A., Blodorn-Schlicht, N., Itschert, G., Karnbach, C. Treosulfan is an effective alkylating cytostatic for malignant melanoma in vitro and in vivo. Melanoma Res. 1999,9(2),125–32.
   PubMedGoogle Scholar
• Harstrick, A.W., Wilke, H., Eberhardt W. et al. A phase I dose escalation trial of intravenous treosulfan in refractory cancer. Onkologie. 1996,19,153–6.
   Web of Science ®Google Scholar
• Sjöö, F., Hassan, Z., Abedi-Valugerdi, M., Griskevicius, L., Nilsson, C., Remberger, M. et al. Myeloablative and immunosuppressive properties of treosulfan in mice. Exper Hematol. 2006,34(1),115–21.
   PubMedGoogle Scholar
• Weissert, R., Wiendl, H., Pfrommer, H., Storch,, M.K., Schreiner  B., Barth, S., et al. Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes. Journal of Neuroimmunology. 2003,144(1–2),28–37.
   PubMedGoogle Scholar
• Scheulen, M.E., Hilger, R.A., Oberhoff, C., Casper, J., Freund, M., Josten, K.M. et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res. 2000,6(11),4209–16.
   PubMedGoogle Scholar
• Casper, J., Knauf, W., Kiefer, T., Wolff, D., Steiner, B., Hammer, U., et al. Treosulfan and fludarabine: A new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood. 2004,103(2),725–31.
   PubMedGoogle Scholar
• Beelen, D.W., Trenschel, R., Casper, J., Freund, M., Hilger, R.A., Scheulen, M.E. et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant. 2005,35(3),233–41.
   PubMedGoogle Scholar
• Koenigsmann, M., Mohren, M., Jentsch-Ullrich, K., Franke, A., Becker, E., Heim, M., et al. High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation. Bone Marrow Transplant. 2004,34(6),477–83.
   PubMedGoogle Scholar
• Sauer, M., Zeidler, C., Meissner, B., Rehe, K., Hanke, A., Welte, K., et al. Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome. Bone Marrow Transplant. 2007,39(3),143–7.
   PubMedGoogle Scholar
• Greystoke, B.S., Carr, T.F. et al. Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities. Br J Haematol. 2008, 142(2),257–62.
   PubMedGoogle Scholar
• Fichtner, I., Becker, M., Baumgart, J. Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL). Eur J Cancer. 2003,39(6),801–7.
   PubMedGoogle Scholar
• Meinhardt, G., Dayyani, F., Jahrsdorfer, B., Baumgart, J., Emmerich, B., Schmidmaier, R. Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients. Br J Haematol. 2003,122(6),892–9.
   PubMedGoogle Scholar
• Schmidmaier, R., Oellerich, M., Baumgart, J., Emmerich, B., Meinhardt, G. Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1. ExperHematol. 2004,32(1),76–86.
   PubMedGoogle Scholar
• Munkelt, D., Koehl, U., Kloess, S., Zimmermann, S.Y., Kalaaeoul, R., Wehner, S., Schwabe, D., Lehrnbecher, T., Schubert, R., Kreuter, J., Klingebiel, T., Essner, R. cytotoxic effects of treosulfan and busulfan against leukaemic cells of pediatric patients. Cancer Chemother Pharmacol. 2008,62,821–30.
   PubMed Web of Science ®Google Scholar
• Shimoni, A., Hardan, I., Shem-Tov, N. Fludarabine and treosulfan: A novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes. Leuk Lymphoma. 2007,48(12),2352–9.
   PubMedGoogle Scholar
• Westerhof, G.R., Ploemacher, A. B., Blokland, I., Dillingh, J.H., McGown, A.T., Hadfield MJD, Down, J.D. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients1. Cancer Res. 2000,60,5470–8.
   PubMed Web of Science ®Google Scholar
• Ploemacher, R.E., Johnson, K.W., Rombouts, E.J., Etienne, K., Westerhof, G.R., Baumgart J., et al. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model. Biol Blood Marrow Transplant. 2004,10(4),236–45.
   PubMedGoogle Scholar
• Reichle, A., Berand A., Andreesen R. Treosulfan-Based tandem high-dose chemo-immuno-therapy with autologous stem cell transplantation for relapsed and refractory aggressive bcelllymphomas. Blood. 2005,106(11).
   Google Scholar
• Wandt, H., Schaefer-Eckart, K., Wilhelm, M. Two allogeneic hematopoietic stem cell transplantations without the use of blood-product support. Haematologica. 2005,90(9),1292–4.
   PubMedGoogle Scholar